Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.

Détails

ID Serval
serval:BIB_E873A1587376
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.
Périodique
Journal of Clinical Oncology
Auteur(s)
van den Bent M.J., Taphoorn M.J., Brandes A.A., Menten J., Stupp R., Frenay M., Chinot O., Kros J.M., van der Rijt C.C., Vecht C.h.J., Allgeier A., Gorlia T.
ISSN
0732-183X
Statut éditorial
Publié
Date de publication
2003
Peer-reviewed
Oui
Volume
21
Numéro
13
Pages
2525-2528
Langue
anglais
Résumé
PURPOSE: Oligodendroglial tumors are chemotherapy-sensitive tumors, with two thirds of patients responding to combination chemotherapy with procarbazine, lomustine, and vincristine (PCV). Temozolomide (TMZ), a new alkylating and methylating agent, has demonstrated high response rates in patients with recurrent anaplastic astrocytoma. We investigated TMZ as first-line chemotherapy in recurrent oligodendroglial tumors (OD) and mixed oligoastrocytomas (OA) after surgery and radiation therapy. PATIENTS AND METHODS: In a prospective, nonrandomized, multicenter, phase II trial, patients were treated with 200 mg/m2 of TMZ on days 1 through 5 in 28-day cycles for 12 cycles. Patients with a recurrence after prior surgery and radiotherapy, and with measurable and enhancing disease on magnetic resonance imaging (MRI) were eligible for this study. Patients with large lesions and mass effect or with new clinical deficits were not eligible. Pathology and the MRI scans of all responding patients were centrally reviewed. RESULTS: Thirty-eight eligible patients were included. In three patients, pathology review did not confirm the presence of an OD or OA. TMZ was generally well tolerated. The most frequent side effects were hematologic; only one patient discontinued treatment for toxicity. In 20 (52.6%) of 38 patients (95% exact confidence interval, 35.8% to 69.0%), a complete (n = 10) or partial response to TMZ was observed. The median time to progression was 10.4 months for all patients and 13.2 months for responding patients. At 12 months from the start of treatment, 40% of patients were still free from progression. CONCLUSION: TMZ provides an excellent response rate with good tolerability in chemotherapy-naive patients with recurrent OD. A randomized phase III study comparing PCV with TMZ is warranted.
Mots-clé
Adult, Antineoplastic Agents, Alkylating/administration & dosage, Antineoplastic Agents, Alkylating/adverse effects, Brain Neoplasms/drug therapy, Brain Neoplasms/pathology, Dacarbazine/administration & dosage, Dacarbazine/adverse effects, Disease Progression, Drug Administration Schedule, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Neoplasm Recurrence, Local/drug therapy, Oligodendroglioma/drug therapy, Oligodendroglioma/pathology, Treatment Outcome
Pubmed
Web of science
Création de la notice
28/01/2008 9:39
Dernière modification de la notice
20/08/2019 17:11
Données d'usage